Home

Merci tourner autour fleur novartis zolgensma press release ange En lhonneur Agitation

Novartis allies with Voyager to develop gene therapies in $1.3bn deal
Novartis allies with Voyager to develop gene therapies in $1.3bn deal

Novartis releases long-term Zolgensma data
Novartis releases long-term Zolgensma data

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor

Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times

AMM européenne pour Scemblix® (asciminib) de Novartis
AMM européenne pour Scemblix® (asciminib) de Novartis

Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma

Novartis to Open New Trial of Zolgensma for Older SMA Patients
Novartis to Open New Trial of Zolgensma for Older SMA Patients

FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace
FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace

EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA

Four Takeaways from the Zolgensma Pricing Storm
Four Takeaways from the Zolgensma Pricing Storm

News Archive | Novartis
News Archive | Novartis

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence

Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube
Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube

Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma
Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters